Search results
Showing 241 to 255 of 264 results for carcinoma
Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545
Discontinued Reference number: GID-TA10418
In development Reference number: GID-TA11831 Expected publication date: TBC
Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma (TA592)
This guidance has been updated and replaced by NICE technology appraisal guidance TA802.
Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine, in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer.
Evidence-based recommendations on pembrolizumab (Keytruda) with chemotherapy before surgery (neoadjuvant) and then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults
Evidence-based recommendations on enfortumab vedotin (Padcev) with pembrolizumab (Keytruda) for untreated unresectable or metastatic urothelial cancer in adults when platinum-based chemotherapy is suitable.
In development Reference number: GID-TA11556 Expected publication date: TBC
This guidance has been withdrawn because the simple discount patient access scheme for QuiremSpheres has been withdrawn.
This guidance has been updated and replaced by NICE technology appraisal guidance 692.
Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer.
Discontinued Reference number: GID-TA10202
In development Reference number: GID-TA11433 Expected publication date: TBC
This guidance has been updated and replaced by NICE technology appraisal guidance 736.
In development Reference number: GID-TA11582 Expected publication date: TBC